Inulin-Butyrate Nanogel for Modulation of Gut Microbiome, Intestinal Barrier, and Regulatory T-Cells in Colitis

Area of Science:

• Gastroenterology and Immunology
• Nanomedicine
• Microbiome Research

Background:

• Inflammatory bowel diseases (IBD) involve a cycle of gut barrier dysfunction, microbiome imbalance, and immune dysregulation.
• Current IBD therapies primarily suppress immunity, neglecting root causes.
• Existing treatments like inulin lack specificity, and butyrate has limited clinical use due to absorption and delivery issues.

Purpose of the Study:

• To develop and evaluate an inulin-butyrate conjugate nanogel (IBN) for targeted IBD therapy.
• To assess IBN's ability to modulate the gut microbiome, intestinal barrier, and immune system in colitis.
• To overcome the limitations of current inulin and butyrate therapies.

Main Methods:

• Development of an inulin-butyrate conjugate nanogel (IBN).
• Administration of IBN to dextran sodium sulfate (DSS)-induced colitis mouse models.
• Analysis of IBN's accumulation in inflamed colon, butyrate release, microbiome modulation, barrier enhancement, and Treg cell differentiation.

Main Results:

• IBN specifically accumulated in the inflamed colon of colitis mice.
• Gut microbial enzymes released high butyrate amounts from IBN.
• IBN improved gut microbiome, enhanced intestinal barrier function, and promoted Treg differentiation, showing robust therapeutic effects.

Conclusions:

• IBN offers a biocompatible strategy to address the multifactorial nature of IBD.
• IBN effectively disrupts the inflammatory cycle and restores gut homeostasis.
• This conjugate nanogel represents a transformative approach for IBD treatment.